menu
techminis

A naukri.com initiative

google-web-stories
Home

>

Bio News

>

Pitt Study...
source image

Bioengineer

2d

read

361

img
dot

Image Credit: Bioengineer

Pitt Study Reveals New mRNA Vaccine Is More Effective and Cost-Efficient to Develop

  • A new mRNA vaccine technology developed by the University of Pittsburgh and Pennsylvania State University shows promise in addressing challenges posed by rapidly mutating viruses.
  • The innovative 'trans-amplifying' mRNA platform could reduce vaccine development costs and enhance efficacy against diverse viral variants.
  • Unlike traditional mRNA vaccines, this new approach involves two discrete RNA fragments: one encoding the antigen and the other encoding the replicase for amplifying the antigen-encoding sequence.
  • By decoupling the mRNA components, the system allows for pre-manufacture of the replicase mRNA, thereby accelerating vaccine development for new viral threats.
  • The trans-amplifying system can amplify the antigen sequence in vivo with significantly less mRNA, reducing production costs while maintaining immunogenicity.
  • Analysis of spike-protein sequences from various SARS-CoV-2 variants led to the creation of a consensus spike protein that aims to elicit broadly neutralizing antibodies targeting multiple viral lineages.
  • Preclinical trials in mice demonstrated that the trans-amplifying mRNA vaccine induced robust neutralizing antibodies against a range of SARS-CoV-2 variants, potentially providing lasting immunity.
  • The innovative vaccine design could transform pandemic preparedness by offering durable immunity with lower dose requirements, impacting vaccine development for other RNA viruses as well.
  • Financial support from institutions played a vital role in the successful execution of the study, facilitating collaborations across disciplines in developing this transformative vaccine platform.
  • Moving forward, scaling up manufacturing and conducting human clinical trials are essential steps to validate the safety and efficacy of the trans-amplifying mRNA platform, potentially revolutionizing vaccine design and accessibility.

Read Full Article

like

21 Likes

For uninterrupted reading, download the app